Short Interest in Sharps Technology, Inc. (NASDAQ:STSS) Expands By 110.0%

Sharps Technology, Inc. (NASDAQ:STSS) saw a significant growth in short interest in February. As of February 15th, there was short interest totalling 899,200 shares, a growth of 110.0% from the January 31st total of 428,100 shares. Currently, 70.3% of the shares of the company are short sold. Based on an average trading volume of 3,140,000 shares, the short-interest ratio is currently 0.3 days.

Institutional Investors Weigh In On Sharps Technology

Hedge funds have recently made changes to their positions in the business. Garden State Investment Advisory Services LLC acquired a new stake in shares of Sharps Technology during the third quarter worth about $26,000. Anson Funds Management LP acquired a new stake in shares of Sharps Technology during the fourth quarter worth about $76,000. Finally, Essential Planning LLC. boosted its stake in shares of Sharps Technology by 22.7% during the fourth quarter. Essential Planning LLC. now owns 199,854 shares of the company’s stock worth $412,000 after buying an additional 37,029 shares during the period. Institutional investors and hedge funds own 17.17% of the company’s stock.

Sharps Technology Price Performance

Shares of STSS traded down $0.02 during mid-day trading on Friday, hitting $0.28. 1,752,872 shares of the company’s stock were exchanged, compared to its average volume of 5,126,340. Sharps Technology has a fifty-two week low of $0.26 and a fifty-two week high of $18.15. The stock has a market cap of $1.57 million, a price-to-earnings ratio of -0.04 and a beta of 1.41. The company has a 50 day simple moving average of $1.19.

Sharps Technology Company Profile

Sharps Technology, Inc, a medical device company, researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States. It offers Sharps Provensa, an ultra-low waste space syringe for the administration of various vaccines and injectable medications. Sharps Technology, Inc was incorporated in 2017 and is based in Melville, New York.